A proteomics approach for the development of sarcoma biomarkers

Publication date: September 2014 Source:EuPA Open Proteomics, Volume 4 Author(s): Tadashi Kondo , Akira Kawai Sarcomas are rare and clinically diverse malignancies, and treatment optimization requires the development of suitable biomarkers. In earlier research employing proteomics analysis, we identified peroxiredoxin 2 as a biomarker of osteosarcoma (OS) that can predict response to neoadjuvant chemotherapy and verified its functional significance in the resistance of OS cells to chemotherapeutic drugs. In addition, in gastrointestinal stromal tumor (GIST), we identified pfetin as a prognostic biomarker and validated its prognostic utility in multi-institutional studies by immunohistochemistry. Here, we present an overview of our progress in sarcoma proteomics and discuss future perspectives. Graphical abstract
Source: EuPA Open Proteomics - Category: Bioinformatics Source Type: research